Background: Vitiligo is a common skin condition resulting from loss of normal melanin pigments in the skin which produces white patches. It mainly affects a younger population and can cause serious cosmetic and social problems. At least three theories about the underlying mechanism of vitiligo have been proposed. Release of a chemical that is toxic to melanocytes is one theory, while another theory says that the melanocytes simply self-destruct. According to the third theory, vitiligo is a type of autoimmune disease. Methods: We performed a prospective study to evaluate the efficacy of the 0.05% clobetasol propionate and 1% pimecrolimus in the treatment of vitiligo. In our study is 25 patients with virtually lesions of vitiligo. Results: Results from this pilot study indicate that topical 1% pimecrolimus is as effective as clobetasol propionate in restoring skin disfiguring due to vitiligo. Discussion: Further studies investigating the safety and efficacy of topical 1% pimecrolimus ointment either as monotherapy or in combination with other therapeutic measures are warranted.
| Published in | Clinical Medicine Research (Volume 4, Issue 6) |
| DOI | 10.11648/j.cmr.20150406.15 |
| Page(s) | 195-197 |
| Creative Commons |
This is an Open Access article, distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution and reproduction in any medium or format, provided the original work is properly cited. |
| Copyright |
Copyright © The Author(s), 2015. Published by Science Publishing Group |
Vitiligo, the Skin Dispigmentation, Progress in Treatment of Vitiligo
| [1] | Mosher DB, Fitzpatrick TB, Ortonne JP, Hori Y. Hypomelanoses and hypermelanoses. In: Freedberg IM, Eisen AZ, Wolff K, et al., eds. Dermatology in General Medicine. 5th ed. New York: McGraw Hill, 1999: 949-60. |
| [2] | Gupta AK, Chow M. Pimecrolimus: a review. J Eur Acad Dermatol Venereol 2003; 17: 493-503. |
| [3] | Marsland AM, Griffiths CE. The macrolide immunosuppressants in dermatology: mechanisms of action. Eur J Dermatol 2002; 12(6): 618-22. |
| [4] | Luger T. Treatment of immune-mediated skin diseases: future perspectives. Eur J Dermatol 2001; 11(4): 343-7. |
| [5] | Mrowietz U. Macrolide immunosuppressants. Eur J Dermatol 1999; 9(5): 346-51. |
| [6] | Hartmann A, Brocker EB, Becker JC. Hypopigmentary skin disorders: current treatment options and future directions. Drugs 2004; 64: 89-107. |
| [7] | Mayoral FA, Gonzalez C, Shah NS, Arciniegas C. Repigmentation of vitiligo with pimecrolimus cream: a case report. Dermatology 2003; 207: 322-3. |
| [8] | Vancoillie G, Lambert J, Nayaert JM. Melanocyte biology and its implications for the clinician. Eur J Dermatol 1999; 9(3): 241-51. |
| [9] | Kostovic K, Nola I, Bucan Z, Situm M. Treatment of vitiligo: current methods and new approaches. Acta Dermatovenerol Croat 2003; 11: 163-70. |
| [10] | Bos JD. Non-steroidal topical immunomodulators provide skin-selective, self-limiting treatment in atopic dermatitis. Eur J Dermatol 2003; 13(5): 455-61. |
| [11] | Ongenae K, Van Geel N, De Schepper S, Vander Haeghen Y, Naeyaert JM. Management of vitiligo patients and attitude of dermatologists towards vitiligo. Eur J Dermatol 2004; 14(3): 177-81. |
| [12] | Kumari J. Vitiligo treated with topical clobetasol propionate. Arch Dermatol 1984; 120: 631-5. |
| [13] | Geraldez CB, Gutierrez GT. A clinical trial of clobetasol propionate in Filipino vitiligo patients. Clin Ther 1987; 9: 474-82. |
| [14] | Clayton R. A double-blind trial of 0-05lobetasol proprionate in the treatment of vitiligo. Br J Dermatol 1977; 96: 71-3. |
| [15] | Lepe V, Moncada B, Castanedo-Cazares JP, Torres-Alvarez MB, Ortiz CA, Torres-Rubalcava AB. A double-blind randomized trial of 0.1% tacrolimus vs 0.05lobetasol for the treatment of childhood vitiligo. Arch Dermatol 2003; 139: 581-5. |
| [16] | Travis LB, Weinberg JM, Silverberg NB. Successful treatment of vitiligo with 0.1% tacrolimus ointment. Arch Dermatol 2003; 139: 571-4. |
| [17] | Grimes PE, Soriano T, Dytoc MT. Topical tacrolimus for repigmentation of vitiligo. J Am Acad Dermatol 2002; 47: 789-91. |
| [18] | Smith DA, Tofte SJ, Hanifin JM. Repigmentation of vitiligo with topical tacrolimus. Dermatology 2002; 205: 301-3. |
| [19] | Tanghetti EA. Tacrolimus ointment 0.10roduces repigmentation in patients with vitiligo: results of a prospective patient series. Cutis 2003; 71: 158-62. |
APA Style
Sadije Halimi, Mybera Ferizi, Antigona Gerqari, Nita Krasniqi, Mergita Ferizi. (2015). Vitiligo and Treatment. Clinical Medicine Research, 4(6), 195-197. https://doi.org/10.11648/j.cmr.20150406.15
ACS Style
Sadije Halimi; Mybera Ferizi; Antigona Gerqari; Nita Krasniqi; Mergita Ferizi. Vitiligo and Treatment. Clin. Med. Res. 2015, 4(6), 195-197. doi: 10.11648/j.cmr.20150406.15
AMA Style
Sadije Halimi, Mybera Ferizi, Antigona Gerqari, Nita Krasniqi, Mergita Ferizi. Vitiligo and Treatment. Clin Med Res. 2015;4(6):195-197. doi: 10.11648/j.cmr.20150406.15
Share This Article
Twitter
Linked In
Facebook
Copy
Download@article{10.11648/j.cmr.20150406.15,
author = {Sadije Halimi and Mybera Ferizi and Antigona Gerqari and Nita Krasniqi and Mergita Ferizi},
title = {Vitiligo and Treatment},
journal = {Clinical Medicine Research},
volume = {4},
number = {6},
pages = {195-197},
doi = {10.11648/j.cmr.20150406.15},
url = {https://doi.org/10.11648/j.cmr.20150406.15},
eprint = {https://article.sciencepublishinggroup.com/pdf/10.11648.j.cmr.20150406.15},
abstract = {Background: Vitiligo is a common skin condition resulting from loss of normal melanin pigments in the skin which produces white patches. It mainly affects a younger population and can cause serious cosmetic and social problems. At least three theories about the underlying mechanism of vitiligo have been proposed. Release of a chemical that is toxic to melanocytes is one theory, while another theory says that the melanocytes simply self-destruct. According to the third theory, vitiligo is a type of autoimmune disease. Methods: We performed a prospective study to evaluate the efficacy of the 0.05% clobetasol propionate and 1% pimecrolimus in the treatment of vitiligo. In our study is 25 patients with virtually lesions of vitiligo. Results: Results from this pilot study indicate that topical 1% pimecrolimus is as effective as clobetasol propionate in restoring skin disfiguring due to vitiligo. Discussion: Further studies investigating the safety and efficacy of topical 1% pimecrolimus ointment either as monotherapy or in combination with other therapeutic measures are warranted.},
year = {2015}
}
TY - JOUR T1 - Vitiligo and Treatment AU - Sadije Halimi AU - Mybera Ferizi AU - Antigona Gerqari AU - Nita Krasniqi AU - Mergita Ferizi Y1 - 2015/12/03 PY - 2015 N1 - https://doi.org/10.11648/j.cmr.20150406.15 DO - 10.11648/j.cmr.20150406.15 T2 - Clinical Medicine Research JF - Clinical Medicine Research JO - Clinical Medicine Research SP - 195 EP - 197 PB - Science Publishing Group SN - 2326-9057 UR - https://doi.org/10.11648/j.cmr.20150406.15 AB - Background: Vitiligo is a common skin condition resulting from loss of normal melanin pigments in the skin which produces white patches. It mainly affects a younger population and can cause serious cosmetic and social problems. At least three theories about the underlying mechanism of vitiligo have been proposed. Release of a chemical that is toxic to melanocytes is one theory, while another theory says that the melanocytes simply self-destruct. According to the third theory, vitiligo is a type of autoimmune disease. Methods: We performed a prospective study to evaluate the efficacy of the 0.05% clobetasol propionate and 1% pimecrolimus in the treatment of vitiligo. In our study is 25 patients with virtually lesions of vitiligo. Results: Results from this pilot study indicate that topical 1% pimecrolimus is as effective as clobetasol propionate in restoring skin disfiguring due to vitiligo. Discussion: Further studies investigating the safety and efficacy of topical 1% pimecrolimus ointment either as monotherapy or in combination with other therapeutic measures are warranted. VL - 4 IS - 6 ER -
Email: